The FDA Modernization Act 2.0 was signed into law eliminating the animal testing mandate in drug discovery.
Hesperos Chief Scientist, Dr. James Hickman, awarded Researcher of the Year at the 2022 BioFlorida conference in Miami
In a recent study published in Biomaterials, a team of researchers led by Hesperos Chief Scientist Dr. J. Hickman established a significant finding to better understand ALS etiology and potential new treatment targets.
Read the Open Letter here We are proud to support this open letter to congress encouraging representatives to pass the FDA Modernization Act. Originally passed in 1938, the Federal Food, Drug, and Cosmetics Act (FFDCA) was … Read More
Financial Times wrote an excellent feature on microphysiological systems, highlighting Hesperos’ Human-on-a-Chip.
Hesperos, Inc. appoints new Chief Executive Officer, Dr. James Kronauge I’m excited to join Hesperos as we expand the capabilities of the Human-on-Chip platform enabling drug developers unprecedented insight into specific disease states, especially for rare … Read More
Hesperos Shows Potential for In Vitro Approach to Replace Conventional Animal Efficacy Studies for Rare Neuromuscular Disorders
1) Validates use of Human-on-a-Chip system to mimic disease mechanisms of rare autoimmune neuropathies that cannot be replicated in animal models.
2) Efficacy data from microphysiological system supported the authorization of a clinical study (NCT04658472) in 2021 through collaboration with Sanofi.